Skip to content

Left Ventricular Pacing to Avoid Cardiac Enlargement Study

Impact of Left Ventricular Pacing on Left Ventricular Systolic Function in High-risk Bradycardia Patients

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01302717
Acronym
LVPACE
Enrollment
0
Registered
2011-02-24
Start date
2010-04-30
Completion date
2019-12-31
Last updated
2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complete AV Block, Sick Sinus Syndrome

Keywords

Left ventricular pacing

Brief summary

In this study, the investigators will examine whether left ventricular pacing is superior to right ventricular apical pacing in preventing deterioration of left ventricular systolic function and cardiac remodeling in patients with bradycardia with high risk for development of pacing-induced heart failure.

Detailed description

In this prospective, we will randomly assign 98 patients who need permanent pacemaker due to complete atrioventricular block or sick sinus syndrome to receive left ventricular pacing (49 patients) or right ventricular apical pacing (49 patients). Patients will be paced with temporary pacemaker lead, and only those with paced QRS duration ≥185 ms will be enrolled. The primary endpoint is left ventricular ejection fraction measured by modified Simpson method at 12 months. The secondary end points include left ventricular systolic end-systolic and diastolic volume, LV strain, NYHA functional class, exercise performance (using treadmill test), quality of life (using SF-36v2), NT-proBNP at 12 months.

Interventions

DEVICELV pacing

The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.

DEVICERV pacing

The right ventricular lead are positioned at the right ventricular apex.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No

Inclusion criteria

* Sinus-node dysfunction or bradycardia due to advanced atrioventricular block * Paced QRS duration ≥185 ms

Exclusion criteria

* Left ventricular ejection fraction \< 50 % * Acute coronary syndrome * If they had undergone percutaneous coronary intervention or coronary-artery bypass surgery within the previous 3 months * if they had a life expectancy of less than 1 year * if they had received a heart transplant

Design outcomes

Primary

MeasureTime frameDescription
Left ventricular ejection fraction (%) at 12 months12 monthsMeasured by modified Simpson's method

Secondary

MeasureTime frameDescription
Left ventricular end-systolic volume (ml) at 12 months12 monthsMeasured by modified Simpson method
Left ventricular end-diastolic volume (ml) at 12 months12 monthsMeasured by modified Simpson method
NYHA functional class12 months
Functional capacity12 monthsmeasured by treadmill test
NT-proBNP12 monthsplasma level

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026